Plant by-products as a valuble source of natural antiglycemic compounds: Economic aspects and alternative raw material sources Authors: Tatjana Đorđević, Jelena Vujetić, Isidora Dickov, Diandra Pintać Šarac Published: 2026 ABSTRACT Plant by-products, often considered as waste in various agricultural and food processing industries, have emerged as a valuable source of natural antidiabetic or antihyperglycemic compounds. These compounds, derived from plant materials that would otherwise be discarded, have the potential to mitigate the global burden of diabetes and offer sustainable solutions for glycemic control. Prominent groups of natural antidiabetic compounds found in plant by-products are polyphenols, as well as bioactive proteins and peptides. In addition, agro-industrial residues such as wheat bran, oat husks, and fruit peels are excellent sources of carbohydrates that can be incorporated into functional foods to help manage diabetes. In addition to their antidiabetic potential, plant by-products contribute to sustainability and waste reduction by turning materials that would otherwise be discarded into valuable resources. Furthermore, the utilization of natural antidiabetic compounds from waste materials promises to improve diabetes management and promote a more sustainable food industry. The paper will address the valorization of agro-industrial by-products as natural sources of antiglycemic compounds, including an economic analysis and exploration of different raw material sources. It will present both the advantages and the key challenges associated with the biological activity, metabolism, bioavailability, and toxicological profiles of these compounds, as well as their economic and environmental implications. Furthermore, the review will highlight the prospects for automating this process through the application of artificial intelligence (AI), which may facilitate greater standardization and efficiency in future development. 1. Introduction Diabetes mellitus (DM) is the most common metabolic disease that manifests as chronic hyperglycemia due to insulin resistance or insufficiency. Diabetes appears in three different forms: (i) type 1 an autoimmune disease that affects 5–10% of individuals that causes immune system attacks and destroys pancreatic cells, preventing the body from producing insulin; (ii) type 2 (which affects 90–95% of patients), in which the body becomes resistant to insulin due to unhealthy diet, lifestyle and obesity; and (iii) gestational diabetes, which sometimes develops in pregnant women due to increased secretion of placental hormones such as hPL (human placental lactogen), estrogen, progesterone, and cortisol that induce pronounced insulin resistance, may resolve after delivery but also increases the risk of developing type 2 diabetes (T2D) in both the mother and the child. According to the latest World Health Organization (WHO) statistics, the number of diabetics worldwide is steadily increasing and is expected to reach 592 million by 2035. In addition, more than $471 billion is spent annually on healthcare for diabetic patients worldwide [1]. The incidence of diabetes is increasing every year and is significantly affecting people’s lives through various health and economic problems. Nowadays, more than one-third of food for human consumption ends up like waste due to different processes along the supply chain. It amounts to about 1.3 billion tons of waste every year. Among them, the agri-food industry is mainly responsible for this generation; some of the examples are presented in Fig. 1. The wine industry generates 9 million tons of grape by-products, while citrus and potato waste amounts to 15 and 12 million tons per year, respectively. These co-products could negatively affect the environment and increase cost parameters during food processing. Since these low-cost, significant and easily available by-products can be an essential source of value-added compounds [2], the aim of food industry is to find new natural products to replace synthetic compounds, which often have toxic effect and carry certain health risks. Different parts of plants, such as seeds, peels, straw, leaves, husks, stems, and roots, are generated as waste streams in different plant processing, such as harvesting and food production [3]. Thus, applying different technological strategies for their utilization could help solve and avoid arising environmental and financial problems. Plant-based by-products could be alternative sources for producing compounds such as peptides, proteins, polyphenols and carbohydrates that offer potential natural antidiabetic agents. Besides, it was noticed that some of them could also exhibit anti-hypertensive and antioxidant activity. Currently, commercial drugs for diabetes treatment such as biguanides, sulfonylureas, and thiazolidinediones have different side effects, such as hypoglycaemia, hepatotoxicity, fatigue, abdominal pain, lactic acidosis, flatulence and diarrheal [4,5]. Previous investigations have focused on anti-diabetic compounds from medicinal plants, grains, fruits, vegetables, and mushrooms, but in this review, we summarize some of the most common compounds from by-products that could be considered as novel bioactive compounds that would have an essential role in diabetes prevention. This article provides the first comprehensive review of the antidiabetic potential of plant by-products from the agri-food industry. It includes articles published between 2000 and 2025, including in vitro research using inhibition of the enzymes α-amylase and α-glucosidase, as well as in vivo testing in animal models. In summarising the current state of knowledge and challenges, we concluded that there is no research that provides a deeper understanding of the biological properties and potential of by-products for their wider use as functional products or antidiabetic phytotherapeutics. The focus of this review was to highlight the biological efficacy of the by-products and their active compounds that may be responsible for the antidiabetic properties. According to our Scopus-based analysis, no study has yet combined the production of antidiabetic compounds from various agro-industrial wastes with assessments of cost-effectiveness and regulatory compliance, highlighting the originality of this work. 2. Prevalence of diabetes mellitus Since 1950, the International Diabetes Federation (IDF) has been at the forefront of the global diabetes community. Since 2000, the IDF has played a critical role in reporting the prevalence of diabetes at national, regional, and global levels. According to IDF’s 2019 data, approximately 463 million people are living with diabetes, representing 9.3% of the world’s adult population aged 20–79 years. It is important to note that many of these cases, about 90%, are due to T2D. These data show that the number of people with diabetes will increase to 578 million by 2030, and it is expected that this number will continue to increase to 700 million by 2045. In 2019, the prevalence of diabetes varied between genders, with an estimated 9.6% in men and 9.0% in women. In addition, the prevalence of diabetes also showed differences across income groups as defined by the World Bank. In 2019, prevalence in high-income countries was 10.4%, followed closely by middle-income countries at 9.5%. In contrast, prevalence in lower-income countries was 4.0% in the same year. It is crucial to highlight that prevalence is expected to increase in all three income groups [6]. Population growth and lifestyle changes have led to a positive caloric balance and a significant increase in obesity prevalence. This increase in obesity prevalence has been substantial, rising from 20.9% to 32.4% between 1994 and 2012. Obesity is an important factor in the occurrence of T2D. In 2000, T2D became the leading cause of death, and since then the mortality rate associated with this disease has continued to increase. Type 2 diabetes mellitus (T2DM) increases mortality mainly through accelerated atherosclerosis, leading to fatal cardiovascular events, kidney damage, and a higher risk of severe infections and complications such as diabetic foot. In 2010, the mortality rate was 14.5%. Currently, T2D is the leading cause of death in women and the second leading cause of death in men [7]. 3. Compounds from by-product with antidiabetic properties The following text summarizes various bioactive compounds with antidiabetic properties, obtained by using different extraction methods from wastes of agri-food industry. The proposed mechanisms of action are also included. 3.1. Carbohydrates Carbohydrates, extracted from various food and lignocellulosic wastes by different physical, chemical, and enzymatic methods, were found to have antidiabetic properties. A previous study reported that carbohydrates have an impact on diabetes through their influence on gastrointestinal viscosity and satiety, as well as through colon fermentation and combating gastrointestinal inflammation [5]. Among them, arabinoxylans (AX) are the most important non-cellulosic polysaccharides found in cereal by-products. Here, we summarize AX, which are obtained from by-product of different cereals. Among cereals, the fine structure of AXs varies considerably, which could exhibit various bioactive properties, such as enhancing immunity and antioxidant effects, strengthening the intestinal epithelial barrier, relieving constipation, and decreasing lipid absorption [8]. They are important as dietary fibers in baked products, but their influence on the gut microbiota and glucose metabolism has also been documented. Arabinoxylan could decrease glucose absorption, which contributes to the attenuation of the postprandial glycemic response by delaying gastric emptying, slowing small intestinal transit, decreasing diffusion rate, and affecting digestive enzymes. In addition, the possibility of gel formation with proteins could lead to a decrease in amino acid levels, resulting in a lower insulin response. The molecular structure of AX, such as the molecular weight, the ratio of arabinose to xylose, and the degree of branching, which is closely related to its viscosity, could have different effects on diabetes by forming arabinoxylan solutions with high or low viscosity. For example, high viscosity of arabinoxylan solution leads to slower gastric emptying that has a positive effect on blood glucose and insulinemia, but the low viscosity arabinoxylan solution could trigger GLP-1, which affects better insulin action [9]. Previous studies have shown that the antidiabetic properties of AX may vary as a consequence of the different AX structure, which is mainly influenced by the ferulic acid content [10]. The IC50 values of the AX extract of wheat bran and aleurone against intestinal α-glucosidase activity ranged from 4.88 to 10.14 mg/mL; they could be achieved by consuming 21–38 g AX per day, which is within the range of recommended fiber doses. Li et al. (2021) [11] found that AX from triticale bran exhibited amylase and glucosidase inhibition in a concentration range between 0.4 and 2.2 mg/mL, and that the cross-linking modification of AX could protect the structure of AX during the digestive environment due to its more compact microstructure. The amylase and glucosidase inhibition rate of AX, which was obtained from wheat chaff, reached 80% using AX solution at a concentration of 4–8 mg/mL. It was found that the presence of hydroxyl groups and hydrogen bonds could play an important role in the inhibition mechanisms due to the interaction with hydroxyl groups of glutamate residues in the enzyme structure. An in vivo antidiabetic study was conducted with mice and the results suggest that AXOS (arabino-xylooligosaccharides) from wheat bran promotes intestinal peptides glucagon-like peptide 1 (GLP-1) capable of regulating food intake by increasing the feeling of satiety [12]. Carbohydrates can also exert their antidiabetic properties by acting as prebiotics. This mechanism is explained in more detail in Section 4. 3.2. Proteins and bioactive peptides By-products from the food industry are a good source for the extraction of proteins. These proteins are valuable for obtaining peptides, with numerous bioactive properties, by enzymatic methods. This review focuses on the proteins and peptides extracted from by-products, such as oil cake and seeds, that express inhibitory properties towards α-amylase and α-glucosidase, and represent promising agents in the clinical treatment of diabetes. Inhibitors of α-amylase can inhibit the activity of α-amylase in saliva and gastrointestinal tract, reduce the absorption of starch and carbohydrates from food, and thus lower blood glucose level. Inhibitors of α-glucosidase can limit carbohydrate absorption in the intestine and control blood glucose levels by reducing the breakdown of starch into glucose, which results in decreased glucose absorption in the intestine and reduced hyperglycemia after a meal. This process involves competitive inhibition of different types of α-glucosidase enzymes in the small intestine. It is important to note that α-glucosidase inhibitors do not stimulate beta cells to secrete insulin, but they can lower insulin levels after a meal and improve insulin sensitivity. Additionally, several peptides prolong the action of the incretins GLP-1 and gastric inhibitory polypeptide (GIP) by inhibiting dipeptidyl peptidase-4 (DPP-4), thereby increasing insulin production and decreasing glucagon secretion. Furthermore, products of carbohydrate digestion, such as glucose, are transported from enterocytes by glucose transporter 2 (GLUT2). It was found that some peptides with different molecular weights can inhibit glucose transport across intestinal epithelial cells by GLUT2 that results in alleviating the postprandial rise in blood glucose levels. Some protein hydrolysates and bioactive peptides have been shown to activate AMP-activated protein kinase (AMPK), thereby improving insulin sensitivity by stimulating glucose uptake in skeletal muscle, promoting fatty acid oxidation in adipose tissue, and reducing hepatic glucose production [13]. In summary, α-glucosidase inhibitors have significant potential as drugs to control blood glucose levels, and many researchers have reported several peptides that have an inhibitory effect on α-glucosidase. Table 1 describes several studies on proteins and peptides derived from by-products that act as α-amylase and α-glucosidase inhibitors. Apricot protein isolates from apricot oil cake showed activity against α-glucosidase with an IC50 value of 343.58 mg/mL [14]. Mazloomi et al. (2021) [15] showed that pepsin hydrolysates from orange seed proteins possessed high antidiabetic activity with 42.35% for α-amylase inhibitory activity and 45.3% for α-glucosidase inhibitory activity at an enzyme-to-substrate ratio of 0.03 and a hydrolysis time of 3.5 h. Similarly, the alcalase hydrolysates of orange seed proteins possessed an α-amylase inhibitory activity of 41.7% for an enzyme concentrate of 3% and a hydrolysis time of 5 h and an α-amylase inhibitory activity of 57% for an enzyme concentrate of 1% and a hydrolysis time of 5 h. The amino acid composition of proteins and peptides was found to play an important role in the inhibition mechanism; peptides containing aromatic residues (Phe, Trp, and Tyr) were considered to be key factors in α-amylase and α-glucosidase inhibitory activities. Ser, Asp, and Glu were important amino acids in peptides with α-amylase and α-glucosidase inhibitory activities [16]. Tryptic, peptic, and alkaline hydrolysates from watermelon protein isolate showed α-amylase inhibition of more than 50% at concentrations ranging from 0.5 to 2.0 mg/mL. The IC50 values of peptic, alkaline, and tryptic hydrolysates were 0.165 mg/mL, 0.149 mg/mL, and 0.234 mg/mL, respectively [17]. 3.3. Polyphenols The present analysis summarizes wastes generated during fruit processing contain significant amounts of polyphenols (Table 2). The main polyphenols found in discarded parts of the fruit (seeds, peel, and pomace) are phenolic acids, flavonoids, anthocyanins and tannins. Polyphenols are an important class of phytochemicals whose consumption provides health benefits to humans. Their antioxidant activity is primarily responsible for their beneficial effects on human health, since oxidative stress is thought to have a role in the onset and progression of numerous chronic illnesses, including cancer, diabetes, cardiovascular, and neurological diseases. A thorough analysis has implicated that polyphenols positively affect diabetes, especially type 2 [20,21]. Polyphenols derived from fruit waste can be used in various formulas to treat diabetes and other diseases, as they are reported to be significantly superior to synthetic products, offering additional benefits and fewer drawbacks. The hypoglycemic effects of polyphenols are primarily due to reduced intestinal absorption of dietary carbohydrates and regulation of enzymes involved in glucose metabolism, as well as improvement of glucose metabolism, cellular functions, insulin action, insulin stimulation, and insulin secretion. One of the best-known effects of polyphenols on carbohydrate metabolism is the reduction of the activity of α-glucosidase and α-amylase, the main enzymes responsible for breaking down carbohydrates into glucose. Besides these two digestive enzymes, polyphenols express their antidiabetic action through the regulation of GLP-1, responsible for postprandial insulin secretion, and through the inhibition of DPP-4 which results in a longer half-life of GLP1, both leading to a decrease in blood glucose levels [22]. Also, dietary polyphenols are reported to ameliorate diabetic complications, including retinopathy, cardiomyopathy, neuropathy, nephropathy, coronary diseases, vascular dysfunction, and renal failure by inhibiting or regulating glycation and thus, the formation of compounds such as pentosidine, pentolysin, argpyrimidine and pyrralin, crossline [4,23]. Furthermore, there is emerging evidence that inflammation is highly implicated in the pathophysiology of diabetes [24], and since polyphenols are known for their antioxidant and anti-inflammatory properties, this could also be a possible mechanism of action in reducing or preventing the onset of diabetes mellitus. According to literature, polyphenolic compounds that are considered exert antidiabetic properties are chlorogenic, caffeic, gallic, ellagic and syringic acids, quercetin, myricetin, resveratrol, tannins, anthocyanins, catechin, epicatechin, epigallocatechin gallate and procyanidins [22,23,25–27]. Grape pomace, consisting of grape skin, seeds and stems, presents a rich source of the above-mentioned compounds, and many more polyphenolics, as only a part of the phytochemicals is transferred from grape to wine during the winemaking process. Even though a part of this by-product is utilized as an organic fertilizer, animal feed and as a raw material for obtaining ethanol, around 9 million tons of grape pomace is generated annually, and its disposal is posing a serious worldwide economic and environmental problem. In the work of Pintać et al. (2018) [28], grape pomace of different grape varieties was efficiently extracted with 6 different solvents in order to obtain various classes of polyphenols. For large scale industries, 80% methanol provided the highest yield of all the present phenolics, especially chlorogenic acid, quercetin and myricetin, ethyl-acetate extracted resveratrol in larger quantities, while acidified aqueous methanolic extract was rich in anthocyanins, catechin and epicatechin. Besides pomace, another winery by-product rich in polyphenols are the grapevine leaves. It is employed to some extent in folk medicine remedies and in culinary delicacies of many countries, but large amounts still remain unused. Grapevine leaves contain different classes and different amounts of polyphenols, compared to pomace. They are a particularly rich source of antidiabetic compounds such as chlorogenic and ellagic acids, quercetin, and its glycosides, and kaempferol 3-O-glucoside [28–30] and should be utilized more as an inexpensive and easily obtainable waste material for the extraction of the named compounds. 4. Carbohydrates, proteins and phenolic compounds as prebiotics in modulating obesity and diabetes mellitus Prebiotics are non-digestible components found in certain foods that selectively support the growth and activity of beneficial bacteria in the gut. Prebiotics contribute significantly to overall digestive health. The interaction between protein hydrolysates and probiotics has been studied in recent years. It was found that whey protein, as a by-product of casein coagulation in the dairy industry, has an advantageous impact on the intestinal microbiota and potential effects as prebiotics [59]. Additionally, arabinoxylan derivates oligosaccharides from agricultural residues after consumption could stimulate the growth of beneficial gut microflora and be regarded as a prebiotic [60]. This section of the article provides a short summary of the use of prebiotic supplementation in the regular diet to modulate the gut microbiota composition in obese and T2DM patients, which is presented in Fig. 2. It also explains how this can have a positive impact on their health. Studies have demonstrated that incorporating prebiotics into a carefully designed diet offers multiple benefits, including reducing gut permeability, bacterial translocation, and inflammation caused by lipopolysaccharides (LPS), while promoting the production of short-chain fatty acids (SCFAs) and bifidogenesis in the gut. Short-chain fatty acids are the primary energy source for beneficial bacteria and have demonstrated anti-inflammatory and antiobesity properties. Additionally, bifidobacteria, which are among the dominant bacteria in the gut microbiota of healthy individuals, are often found in lower levels in those with metabolic disorders. Prebiotic intake has also been linked to reduced levels of total cholesterol, lipogenesis, LDL triglycerides, and adiposity, as well as a decreased risk of cardiovascular diseases—key health concerns for individuals with obesity and T2DM [4]. Chemically more complex dietary fibers such as polyphenols, arabinoxylan, and protein hydrolysates are not absorbed in the small intestine. Instead, they reach the colon, where the gut microbiota metabolizes them. The colonic fermentation of these compounds promotes a series of prebiotic effects, including modulation of the intestinal microbiota. In addition, metabolites generated by colonic metabolization enter the bloodstream through absorption in colonocytes and are distributed to organs and tissues to perform their antidiabetic effects. The prebiotic mechanism based on the fermentation of carbohydrates into short-chain fatty acids represents their primary and most significant antidiabetic mechanism. The SCFAs such as acetate, propionate, and butyrate produced after fermentation of carbohydrates can activate specific G-protein-coupled receptors (such as GPR41 and GPR43), thereby stimulating GLP-1 secretion, enhancing insulin production, and improving insulin sensitivity [61]. In addition, SCFAs are not only a crucial class of metabolites in the gut, produced by gut microbiota through metabolizing dietary fiber but also play a role as signalling molecules to improve anemia, brain development, colorectal cancer, depression, obesity, and diabetes [62]. Daily consumption of prebiotics can help modulate the gut microbiota composition and enhance the general health of individuals with obesity and T2DM. Therefore, in future research, more extensive studies should be conducted to provide favorable evidence for -biotics to improve pre-diabetes conditions and T2DM, thereby providing a new therapeutic tool to prevent and delay the development of pre-diabetes to T2DM [63]. 5. DM implications in other chronic diseases T2DM is considered a systemic metabolic disease that affects nearly every organ system and leads to severe secondary complications, including cardiovascular diseases, nephropathy, retinopathy, diabetic foot, osteoporosis, hepatic damage, increased susceptibility to infections, and certain malignancies. A central pathogenic factor in the development and progression of T2DM is insulin resistance, a condition in which peripheral tissues, particularly skeletal muscle, liver, and adipose tissue, exhibit reduced responsiveness to insulin. To compensate, pancreatic β-cells increase insulin secretion, leading to hyperinsulinemia. Over time, the compensatory mechanism fails, resulting in chronic hyperglycemia and the eventual manifestation of overt diabetes. Insulin resistance is influenced by a combination of genetic predisposition, central (abdominal) obesity, sedentary lifestyle, aging, poor dietary habits, chronic stress, hormonal disorders (such as polycystic ovary syndrome), and certain medications (e.g., glucocorticoids or antipsychotics). These factors not only drive hyperglycemia but also contribute to the clustering of metabolic abnormalities, including dyslipidemia, hypertension, and pro-inflammatory states, which further exacerbate the risk of both microvascular and macrovascular complications in individuals with T2D. How T2DM contributes to each condition is explained in the following paragraphs, briefly mentioning the implicated mechanisms. T2DM significantly increases cardiovascular risk: insulin resistance disrupts endothelial PI3K/Akt signaling and diminishes nitric oxide (NO) production, leading to endothelial dysfunction. Hyperglycemia and advanced glycation end-products (AGE) formation cause oxidative stress and inflammation, which promote vascular adhesion molecule expression and atherogenesis. Increased reactive oxygen species (ROS) in cardiomyocytes due to altered substrate metabolism causes mitochondrial dysfunction, fibrosis, impaired calcium handling, and cardiac remodeling, manifesting as coronary artery disease, heart failure, and diabetic cardiomyopathy [64–66]. In the kidney, persistent hyperglycemia triggers glomerular hyperfiltration and activation of the renin–angiotensin–aldosterone system, which, together with the formation of AGEs, activation of protein kinase C (PKC), and oxidative stress, provokes mesangial expansion, thickening of the glomerular basement membrane, and eventually glomerulosclerosis [67–69]. In the retina, similar mechanisms such as excessive flux through the polyol pathway, PKC activation, overproduction of AGEs, and mitochondrial overproduction of ROS contribute to endothelial dysfunction, inflammation, and breakdown of the blood–retinal barrier, underpinning diabetic retinopathy [70,71]. Peripheral neuropathy, which underlies diabetic foot complications, may arise from hyperglycemia-induced mitochondrial ROS and associated neuronal injury, compromised neurovascular support, and inflammation [72]. Bone metabolism is also disrupted: AGE accumulation in bone collagen and chronic inflammation impair osteoblast function and increase bone fragility, contributing to osteoporosis in T2DM [73,74]. In the liver, insulin resistance promotes lipid accumulation, inflammation, and profibrotic signaling, leading to non-alcoholic fatty liver disease (NAFLD) and potentially non-alcoholic steatohepatitis (NASH) [75]. Immune dysfunction in T2DM, driven by hyperglycemia, AGE-RAGE signaling, oxidative stress, and chronic low-grade inflammation, impairs innate immune responses—such as macrophage and neutrophil function—and increases susceptibility to infections [76]. T2DM is not only a metabolic disorder but also creates a procarcinogenic environment that increases the risk of developing various malignancies. Chronic hyperglycemia, hyperinsulinemia, and enhanced IGF-1 signaling, together with chronic inflammation and oxidative stress, stimulate proliferative and antiapoptotic pathways in cells [77]. These mechanisms increase DNA mutations and the potential for malignant transformation, resulting in a higher risk of liver, pancreatic, colorectal, breast, and urinary tract cancers. A substantial body of experimental and clinical evidence also supports the characterization of Alzheimer’s disease (AD) as “type 3 diabetes”, reflecting brain-specific insulin resistance and metabolic dysfunction. Postmortem human studies and intracerebral streptozotocin (IC-STZ) animal models demonstrate profound impairments in insulin and IGF signaling, including reduced activity of the insulin receptor, IRS-1, PI3K, and Akt pathways, which are essential for neuronal survival and synaptic maintenance. These defects lead to decreased GLUT4-mediated glucose uptake and chronic cerebral energy deficiency, paralleling peripheral diabetic mechanisms. Concurrently, brain insulin resistance contributes to core AD pathophysiology by impairing amyloid-β clearance, promoting tau hyperphosphorylation, increasing oxidative stress, disrupting mitochondrial function, and promoting neuroinflammation. Because these metabolic abnormalities closely mirror those seen in T2D, yet occur predominantly within the central nervous system, many researchers describe AD as a brain-localized metabolic disorder, justifying the term “type 3 diabetes”. Given that T2DM is a multifaceted and intricate condition, the therapy must also be comprehensive [78–81]. Apart from the aforementioned complications, increasing attention is being paid to the reproductive health of individuals with T2DM. Chronic hyperglycemia and insulin resistance can lead to significant hormonal and metabolic imbalances that negatively affect fertility in both women and men. In women, T2D is often associated with menstrual irregularities, anovulation, and polycystic ovary syndrome (PCOS), which collectively reduce the likelihood of natural conception. Hyperinsulinemia and increased androgen levels can impair follicular development, oocyte quality, and endometrial receptivity, further decreasing fertility and increasing the risk of early pregnancy loss. In men, T2D can lead to decreased sperm count and motility, impaired sperm DNA integrity, erectile dysfunction, and altered hormone levels, including low testosterone, all of which compromise reproductive potential. Additionally, obesity, dyslipidemia, chronic inflammation, and oxidative stress commonly present in T2D exacerbate these reproductive issues. Effective management, including glycemic control, lifestyle modifications, weight reduction, and treatment of associated hormonal disturbances, is crucial to improve fertility outcomes in this population [82,83]. 6. ADME and bioavailability of compounds from agro-industrial waste The ADME (absorption, distribution, metabolism and excretion) behavior of arabinoxylans, bioactive peptides, and phenolics fundamentally shape their antidiabetic potential. Arabinoxylans (AXs) resist digestion in the upper gastrointestinal tract due to their high molecular weight, extensive branching, and lack of endogenous human xylanolytic enzymes, resulting in minimal small-intestinal absorption [84]. Instead, AXs reach the colon largely intact, where they undergo microbial fermentation by Bacteroides, Bifidobacterium, and other fiberdegrading taxa, producing arabinoxylan-oligosaccharides (AXOS), monosaccharides, and SCFAs [85,86]. These fermentation products, particularly SCFAs, are absorbed by colonocytes and enter systemic circulation, where they contribute to metabolic, immunomodulatory, and gut-barrier– supporting functions [86]. Because native AXs have limited solubility and low bioavailability, their physiological effects depend primarily on colonic fermentation, whereas AXOS exhibit significantly higher fermentability and bioavailability due to their lower degree of polymerization and improved accessibility for microbial enzymes [87]. Thus, the health impacts of AXs arise not from direct absorption but from their microbial metabolism and the systemic actions of derived SCFAs. Bioactive peptides and proteins derived from plant by-products undergo characteristic ADME processes that shape their physiological activity. After ingestion, plant proteins are denatured and hydrolyzed by gastric and pancreatic enzymes into smaller peptides and amino acids, a process essential for releasing bioactive fragments [88]. Their absorption depends largely on molecular size: di- and tripeptides are efficiently transported through the intestinal epithelium via the proton-coupled transporter PEPT1, while larger peptides show limited permeability and often rely on paracellular routes or endocytosis [89,90]. Once in systemic circulation, peptides may exert biological functions or be further hydrolyzed by plasma peptidases, meaning their activity is determined by both transport efficiency and metabolic stability [91]. Many bioactive peptides are only generated after gastrointestinal digestion and thus act as “propeptides,” with their functionality emerging from enzymatic release during digestion or food processing [92]. Because only a fraction of ingested peptides remains intact during digestion and transit to target tissues, bioavailability remains moderate but biologically meaningful, influenced by peptide sequence, hydrophobicity, and resistance to proteolysis [93]. Unabsorbed peptides reaching the colon may undergo further microbial metabolism, contributing indirectly to metabolic effects. Processing approaches such as enzymatic hydrolysis or fermentation of plant by-products can enhance the generation of low-molecular-weight peptides with improved absorption and stronger biological effects [94]. Overall, the ADME profile of plant-derived peptides reflects a balance between digestive release, epithelial transport, metabolic stability, and physiological activity. Polyphenols from plant by-products, such as fruit peels, seeds, and cereal brans, exhibit low intrinsic bioavailability due to their complex chemical structures and interactions with other dietary components. After ingestion, polyphenols undergo partial hydrolysis in the stomach, but the majority reach the small intestine largely intact, where enzymatic hydrolysis by intestinal enzymes or gut microbiota releases aglycones, the bioactive forms that can be absorbed [95,96]. Absorption efficiency is influenced by molecular size, glycosylation, and polymerization; simple phenolic acids are absorbed more readily than flavonoid glycosides or polymeric proanthocyanidins [97]. Once absorbed, polyphenols undergo extensive phase I and II metabolism in enterocytes and the liver, producing glucuronides, sulfates, and methylated derivatives, which determine their systemic bioactivity [98]. Unabsorbed polyphenols reach the colon, where gut microbiota further metabolize them into smaller phenolic compounds, which can then be absorbed and contribute to biological effects, including antioxidant, anti-inflammatory, and antidiabetic activities [99]. The overall bioavailability of polyphenols is thus shaped by a complex interplay between chemical structure, intestinal absorption, microbial metabolism, and conjugation reactions, highlighting the importance of both parent compounds and microbial metabolites in mediating health benefits. The ADME and bioavailability profiles of arabinoxylans, peptides and proteins, and polyphenols significantly influence their physiological efficacy. Arabinoxylans, largely non-digestible fibers, reach the colon where microbial fermentation produces short-chain fatty acids, mediating prebiotic and metabolic effects. However, their systemic bioavailability is minimal, limiting direct effects outside the gut [84,100]. Bioactive peptides and proteins from plant by-products require enzymatic hydrolysis for release of active fragments and display moderate absorption through peptide transporters, yet systemic activity can be constrained by enzymatic degradation during transit [92,93]. Polyphenols exhibit low intrinsic absorption, extensive first-pass metabolism, and dependence on gut microbial transformation for biological activity, resulting in wide interindividual variability in clinical responses [95,98]. Despite these limitations, numerous clinical studies demonstrate meaningful health outcomes, such as improved glycemic control, lipid modulation, antioxidant effects, and anti-inflammatory responses, supporting the translational relevance of these compounds [94,99]. Enhancing ADME through advanced formulation strategies, including microencapsulation, co-administration with absorption enhancers, enzymatic pre-treatment, or development of targeted-release systems, can increase stability, absorption, and bioactivity, thereby improve the clinical efficacy of these bioactive ingredients and enable their use as functional foods or nutraceuticals. 7. Extraction and standardization challenges The extracts with summarized bioactive compounds-such as polyphenols, carbohydrates, proteins and peptides, possess multifunctional pharmacological properties, ranging from antioxidant to antidiabetic activity [101]. Most of these natural bioactives are increasingly incorporated into pharmaceuticals, nutraceuticals, functional foods, and even cosmetic formulations [102]. To maximize their therapeutic potential, it is essential to design and implement optimized extraction techniques that maintain the stability, recovery efficiency, and bioactivity of these compounds [103]. The limitation factor in determining the chemical composition and bioactivity of natural products is the choice of extraction methods [104]. Conventional extraction methods such as maceration or Soxhlet extraction are simple but these processes associated with high organic solvent consumption, and longer processing times as well as, low extraction efficiency and align with possibility of degradation of thermolabile components. Emerging green extraction techniques such as microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), supercritical fluid extraction (SFE), pressurized liquid extraction (PLE), enzymes and natural deep eutectic solvents (NaDESs) outperform conventional methods in terms of minimized of solvent usage and time of extraction, as well in higher yields [105]. Despite different applied extraction methods, a major challenge in the field of natural product extraction is standardization. The selection of solvents is crucial in determining the efficiency and selectivity of the extraction process. Various factors influence this decision, ranging from the chemical properties of the target compounds to practical considerations like sustainability and cost-effectiveness. Emphasizing that solvent choice and process parameters ultimately define extract composition and quality. In addition, a critical limitation for both of these approaches is in the variability of raw material composition, influenced by factors such as cultivar, environmental conditions, and post-harvest processing, which affects extract yield, composition, and bioactivity, complicating standardization and regulatory mechanisms. Although numerous extraction techniques have proven effective on a laboratory scale, their industrial-scale application poses both technical and economic challenges. However, with big data and AI, a new green extract technology is being developed to ease to standardization for extraction of bioactive compounds from wastes of agri-food industry. For future scale-up, it is critical to choose not only appropriate extraction methods but also the suitable regulatory path (labelling as novel food or novel food with health claim), depending on the intended market and functional role. Industry 4.0 technologies offer significant opportunities to enhance the sustainability of green and novel extraction processes. 8. Toxicology of carbohydrates, proteins and phenolic compounds In order to determine the potential applications of target compounds in the pharmaceutical and food industries, it is essential to estimate whether they affect cell growth and proliferation or exhibit cytotoxicity toward human cell lines. Previously, it has been found that phenolic compounds have beneficial effects on health. However, consuming these compounds in high concentrations can induce toxicological effects because they can act as prooxidants. The possible toxic effects on health can be attributed to their ability to propagate reactive species and, consequently, the inflammation process. Moridani et al. (2002) [106] estimated the toxicity of flavonoids and found that galangin caused toxicity at 105 μmol. In contrast, epicatechin was found to have one of the lowest toxicity levels (LD50 = 17,000 μmol) [107]. Conversely, research has indicated that phenolic extracts, which predominantly comprise chlorogenic acid, led to a reduction in cell viability in human leukocytes by approximately 20% at a concentration of 100 μg/mL. Importantly, no genotoxic DNA damage was identified within the analyzed cell line. Additionally, elevated doses of green tea polyphenols, specifically in the range of 0.5%–1% in the diet, have been associated with nephrotoxicity and hepatotoxicity [108]. Thus, the consumption of phenolic compounds must be approached with due diligence, as their health effects can vary significantly depending on the concentration administered [4]. There are only a limited number of studies that have investigated the effects of arabinoxylan-derived compounds on human cell lines, particularly on cytotoxicity and antiproliferative activity. One such study tested the cytotoxicity of arabinoxylan derived from dried distillers’ grains on normal human colon cells using different concentrations (125, 250, 500, and 1000 μg/mL). The results showed that arabinoxylan did not have any noticeable effect on the proliferation or morphology of CCD 841 CoN cells, regardless of the concentration tested. Moreover, arabinoxylan did not exhibit any toxic effects on the standard human colon cell line under investigation [109]. Protein hydrolysates are approved for use in food products across most European countries, as they are generally recognized as safe. In fact, some protein extracts have been found to be safe for intake in doses ranging between 2500 mg/kg and 5000 mg/kg [109]. Other studies have shown that protein hydrolysates are not toxic and do not result in mortality even when consumed in high doses of up to 5000 mg/kg [110]. In order to ensure the safety of products designed for human consumption, it is critical to assess their acute toxicity first. While previous research has revealed promising indications of the potential antidiabetic effects of arabinoxylan, phenolic compounds, and protein hydrolysates, further in vivo and in vitro studies are necessary to confirm these findings. This summary will also help to identify the mechanism of action and the main factors responsible for this activity and toxicity. In particular, there is a need to investigate how these compounds interact with the human body, including how they are metabolized and excreted, as well as possible side effects or adverse reactions that may occur. By conducting rigorous and comprehensive studies of these compounds, we can better understand their potential health benefits and side effects and develop safer and more effective products for human consumption. 9. Economic evaluation of phenol extraction from orange peels–commercialization and circular economy Since oranges are the largest representative of citrus fruits and thus, generate abundant industrial by-products of orange peels is abundant, a summary of applying different extraction methods for producing potential phenolic compound with anti-diabetic properties is explain on this source. Integrating solutions for producing value-added products accompanying the food industry is important because it can ensure higher economic sustainability in agro-industrial processing and eliminate or reduce waste. It is well known that most compounds obtained from waste exhibit different biological and functional properties. However, with its application in the market value chain in the future, it could be important to check whether the new valorisation strategy being developed is viable from an economic and sustainable perspective. This section presents a comparative financial analysis of four extraction technologies for recovering phenolic compounds from orange peel waste material. The analysis includes capital costs, operating costs, annual revenue, net profit, and payback time. When orange peel is sourced locally from juice processors, it is typically considered a zero-cost by-product and is therefore excluded from the cost calculation. To enable a fair comparison of the costs for each extraction process, different amounts of waste need to be processed to obtain the same quantity of final product-depending on the efficiency of each method and the operation costs were adjusted according to the required input mass of material for extraction. Cost estimations for capital investment and operational expenses are based on the methodology reported by Arias et al. (2025) [111] while the sale price of obtained phenolic compounds is assumed to be $0.02 per gram, in line with average market data reported by Jin et al. (2021) [112]. This price was used for all net profit and payback time calculations. As shown in the results Table 3, microwave-assisted extraction (MAE) demonstrates the highest profitability and the shortest payback period, making it the most attractive option from an investment standpoint. Ultrasound-assisted extraction (UAE) also shows promising results, with a payback period of less than one year, indicating good economic viability. In contrast, conventional extraction methods are not financially viable under the assumed market conditions, primarily due to low yield and high processing costs. Subcritical water extraction (SWE) is economically feasible but involves higher initial capital costs, which result in a longer payback time compared to the other emerging technologies. By-products from agricultural and food processing industries are increasingly explored as sources of bioactive compounds for novel foods and health claims. Utilizing these by-products aligns with sustainability and circular economy principles but requires rigorous evaluation of safety and efficacy. Therefore, any economic feasibility analysis must include the costs of regulatory approval and certification. According to literature, the average cost required for novel food approval is estimated at €600,000, while the cost for obtaining novel food authorization with a health claim may reach approximately €1,000,000 [68]. As shown in the previous table, conventional extraction methods are often not suitable for scale-up. In this context, three emerging technologies were compared for their potential to extract phenolic compounds from orange peels, along with their feasibility under novel food or novel food with a health claim regulatory scenario (Table 4). The analysis demonstrates that payback time increases when certification costs are included. When targeting a novel food label with health claim, UAE becomes less economically viable, whereas MAE and SWE remain attractive and potentially profitable investments. Therefore, it could be concluded that antidiabetic phenolic compounds can be successfully obtained from agroindustrial by-products such as orange peels. Furthermore, orange peels are a rich source of glucans, pectin and hemicellulose, which adds value when integrated into a circular economy model. In addition, Boukroufa et al. (2015) [113] previous proposed sequential method extraction for obtained essential oil, phenolic compound and pectin from orange peel. For instance, coupling phenolic extraction with sugar production in a single process could reduce production costs and improve payback time, reinforcing the economic and environmental sustainability of the entire operation. Therefore, integrating all of these aspects is essential when evaluating strategies for valorizing agro-industrial by-products. As the data in the tables suggested, the use of emerging technologies provides greater benefits in terms of economic sustainability. Despite their improved efficiency and lower environmental impact, their industrial application still requires considerably higher capital investment and precise process control to maintain scalability and reproducibility [114]. Therefore, further process optimization is required to achieve even better results. In this context, the adoption of Industry 4.0 technologies, including digital sensors, AI-based process control, real-time monitoring, and blockchain, can minimize variability caused by raw material heterogeneity, optimize yields, and ensure process reproducibility [114]. Moreover, the transition from traditional to digitalized systems strengthens the link between green extraction and Industry 4.0. Integrating process modelling, real-time monitoring, artificial intelligence (AI), and smart sensors improves process control, reproducibility, and resource efficiency. Importantly, modern extraction platforms are inherently more compatible with AI integration than conventional ones, due to their reliance on measurable parameters, digital control, and real-time data acquisition, enabling intelligent, adaptive optimization for sustainable industrial application. At the same time, it strengthens the sustainability and efficiency goals of green extraction within circular bioeconomy frameworks. Positioning these processes within an Integrated Biorefinery framework supports circular economy principles by enabling co-production of multiple value-added compounds, enhancing both economic and environmental sustainability. 10. Conclusions and future outlook This review summarizes phytochemicals that could be easily obtained from waste materials and utilized as beneficial agents for treating diabetes, especially type 2. The focus was set on carbohydrates, proteins, and polyphenolic compounds with proved in vitro and/or in vivo antidiabetic activity. It is highly suggested that instead of discarding by-products generated from the agricultural-food industry, appropriate extraction procedures should be employed for recovering these components from wastes. Such practices would yield useful compounds and their different formulations could be used in the treatment of various diseases, including diabetes. Furthermore, such practices would facilitate the exploitation of different bioactive raw materials, which is very important as their disposal currently causes serious environmental and economic problems. The potential of these phytochemicals is related to their safety, affordability, low cost, and high availability. It is therefore advisable to utilize waste for the recovery of functionally essential constituents which are considered to be more superior to synthetic products as they provide much more benefits with less side-effects or none at all. In the future, it will be beneficial to develop biorefinery frameworks that extract phenolic compounds, bioactive peptides, and oligosaccharides from agro-industrial residues with potential antidiabetic activity, in sequential extraction process integrate with AI-driven quality control and standardized logistics systems within the context of Industry 4.0 technologies. Current challenges include the high variability of agro-industrial residues, which differ markedly in chemical composition and therefore require distinct pretreatment and extraction strategies. Additionally, a large portion of these residues is seasonal, causing feedstock availability to fluctuate throughout the year and making continuous operation and economic feasibility difficult to sustain. By enabling real-time monitoring, predictive modelling, and automated classification of by-products from various sources based on composition and functional properties, artificial intelligence can help address these shortcomings and facilitate effective sorting of seasonal and diverse feedstocks, thereby enabling flexible, scalable operations. Together, these digital tools embed the zero-waste concept throughout the entire technological chain, enhancing both resource efficiency and process profitability. At the same time, adopting standardized, digitally integrated logistics improves traceability, resource utilization, and overall operational efficiency, reinforcing circular-economy principles. Therefore, including Industry 4.0 aspects could effectively overcome current problems posed by feedstock variability and seasonality, making multiproduct biorefineries more sustainable and economically viable for producing potential antidiabetic components.